| Ytd | -12.35% | |
| 1y | 138.92% |
| Open | 37.79 | Prev Close | 37.65 | Low | 34.71 | High | 37.79 | Mkt Cap | 138.05M |
| Vol | 50.57K | Avg Vol | 52.86K | EPS | -0.78 | P/E | N/A | Forward P/E | -42.03 |
| Beta | 0.63 | Short Ratio | 1.50 | Inst. Own | 14.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 33.75 | 200-d Avg | 32.19 | 1yr Est | 35.00 |
VTVT News
vTv Therapeutics (NASDAQ:VTVT) reported quarterly earnings of $1.65 per share which beat the analyst
Wall Street analysts changed outlook on top names. See ratings page for upgrades, downgrades, and in
Wall Street analysts change outlook on top companies. See analyst rating changes and their thoughts
Top Wall Street analysts changed their outlook on top names, including WLTH, FPI, CAG, VIV, and GIS.
Top Wall Street analysts changed outlook on certain stocks. See analyst ratings and advice on Rush S
Evercore ISI Group analyst Michael DiFiore initiates coverage on vTv Therapeutics (NASDAQ:VTVT) w
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.58) per share which beat the analyst
vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the developm
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the pric
Roth Capital analyst Adam Walsh initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy r
TD Cowen analyst Ritu Baral initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy ratin
HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy
vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced a Phase
BTIG analyst Kambiz Yazdi initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.08) per share which missed the analy
HC Wainwright & Co. analyst Emily Bodnar reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.92) per share which missed the analy
vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clini
vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced the app
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.77) per share which beat the analyst
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on vTv Therapeutics (NASDAQ:VTVT)
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.55) per share which beat the analyst
vTv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hol
Alliance Global Partners analyst James Molloy initiates coverage on vTv Therapeutics (NASDAQ:VTVT
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.88) per share. This is a 72.41 perce
vTv Therapeutics faces a setback as the FDA places a clinical hold on its cadisegliatin program, imp
vTv Therapeutics Inc. (NASDAQ:VTVT), a late stage biopharmaceutical company with an innovative clini
Gainers Harbor Custom Development, Inc. (NASDAQ: HCDI) rose 74.2% to $1.50 after surging 24% on Th
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the co
Here's a roundup of top developments in the biotech space over the last 24 hours:
Gainers Missfresh Limited (NASDAQ: MF) jumped 51.1% to close at $0.2450 on Wednesday.
On Wednesday, 807 companies reached new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.